VRCA — Verrica Pharmaceuticals Inc.

Summary of Verrica Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $14.3 million for Q3 2025, a significant increase from a negative revenue of $1.8 million in Q3 2024.
• Revenue Breakdown:
  • $10.7 million from Torii milestone and collaboration revenue.
  • $3.6 million from net YCANTH revenue, up from $84,000 in the previous year.
• Gross Product Margins: 79.1%.
• GAAP Net Loss: $0.2 million ($0.03 per share), compared to a net loss of $22.9 million ($4.88 per share) in Q3 2024.
• Non-GAAP Net Income: $1.2 million ($0.13 per share), compared to a net loss of $20.2 million ($4.30 per share) in Q3 2024.
• Cash Position: $21.1 million as of September 30, 2025, supported by $18 million in cash milestone payments from Torii.

2. Strategic Updates and Business Highlights

• YCANTH Growth:
  • 120% year-over-year increase in dispensed applicator units for YCANTH, totaling 37,642 units for the first nine months of 2025.
  • Continued adoption among healthcare providers, with a 5% quarter-over-quarter growth in Q3.
• New Initiatives: Launch of YCANTH Rx, a non-dispensing pharmacy aimed at simplifying the prescription process and improving patient access.
• Pipeline Development:
  • Initiation of Phase III clinical program for YCANTH in common warts, with first patient dosing expected in December 2025.
  • Positive FDA feedback on VP-315 for basal cell carcinoma, with plans for a Phase III study design confirmed.
• Regulatory Milestones: Anticipation of a Marketing Authorization Application filing for YCANTH in the EU by Q4 2026, following positive feedback from the European Medicines Agency.

3. Forward Guidance and Outlook

• Sales Expectations: Anticipation of continued momentum into Q4 2025, despite expected seasonal slowdowns in November and December.
• Sales Force Expansion: Plans to increase the sales force from 45 to 50 representatives in 2026 to enhance market penetration.
• Pipeline Potential: Strong prospects for both YCANTH and VP-315, with expectations of robust growth and potential partnerships to support development and commercialization.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Anticipated traditional slowdowns in sales during the holiday season may affect Q4 performance.
• Competitive Pressures: The primary competitor remains the "watch and wait" approach among clinicians, which Verrica aims to overcome by promoting YCANTH as a best-in-class treatment.
• Regulatory Delays: The timeline for the EU filing is extended due to procedural requirements, including securing a pediatric waiver, which could delay commercialization efforts.

5. Notable Q&A Insights

• Demand in Q4: Management noted that the positive momentum seen in September has continued into Q4, although some seasonal slowdowns are expected.
• Sales Force Productivity: New hires are expected to ramp up productivity early in 2026, with a focus on both expanding existing prescriber engagement and reaching new markets.
• YCANTH Rx Feedback: Initial feedback from key opinion leaders (KOLs) has been positive, indicating that the new pharmacy model could streamline the prescription process and enhance growth.
• Metrics for YCANTH Rx: While specific KPIs are not yet disclosed, typical metrics such as time to fill and fulfillment rates will be monitored to assess the initiative's success.

This summary encapsulates the key aspects of Verrica Pharmaceuticals' Q3 2025 earnings call, highlighting the company's financial performance, strategic initiatives, future outlook, and challenges faced in the current market landscape.